Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Electron Transfer Dissociation Spectrometry

By Drug Discovery Trends Editor | May 24, 2010

Bruker has presented a number of milestone achievements in the analysis of intact proteins at the 58th ASMS Conference, including direct sequencing and characterization using Bruker’s new maXis ETD system. The high mass accuracy, resolving power and dynamic range which are essential to dissect complex patterns of product ions in protein fragmentation allowed, for the first time, performing ETD-based tandem mass spectrometry on biomolecular ions above 60 kDa routinely. These results represent a new record for the mass spectrometric sequencing of intact proteins and unequivocally demonstrate the dramatic advantages of maXis ETD technology in ETD-based top-down protein structural analysis.

“An increasing proportion of new therapies in pharmaceutical development are proteins. At the same time, many first-generation biotherapeutics will soon come off patent protection, and thus the need for rapid and reliable total protein characterization has never been higher,” commented Dr. Michael Schubert, Executive Vice President at Bruker Daltonics. “We believe that the new maXis ETD has unique and unprecedented capabilities that far exceed what’s feasible with intact protein ETD on ion trap/orbitrap hybrid instruments.”

Since the launch of the novel ultra-high resolution (UHR) QqTOF instrument maXis at ASMS 2008, a number of leading scientists have taken the opportunity to explore the potential of the unique combination of high mass range, resolution and speed in the direct LCMS examination of recombinant proteins. “The results are extraordinary, and maXis stands alone in this type of analysis,” commented Bruker’s Head of LCMS Applications Development Dr. Carsten Baessmann. “Isotopic definition of proteins over 30kDa and at part-per million mass accuracy under LC conditions are straight-forward now on our maXis ETD, making the confirmation of correct expression unequivocal.”

Several examples will be demonstrated at Bruker’s Users Meeting on Sunday and during the ASMS scientific program. The recent transfer of Bruker’s leading ETD technology to maXis has allowed precise intact protein analysis as well as comprehensive direct protein gas-phase sequencing. An example of particular note is the direct ETD sequence analysis of intact proteins like serotransferrin and monoclonal antibodies up to a MW of 150 kDa featured by Professor Yury Tsybin of the EPFL (Swiss Federal Institute of Technology Lausanne) in his Thursday 8:30 AM oral presentation at ASMS. Further examples of top-down intact protein identification and characterization will be presented in various poster sessions at ASMS.

Bruker Daltonics


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50